![](/images/graphics-bg.png)
Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
Joint Authors
Xie, Yingjun
Yao, Xiaoxiao
Zhang, Dan
Sheng, Jiyao
Zhang, Xuewen
Xiang, Yien
Yang, Yongsheng
Source
Journal of Immunology Research
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-03-26
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Primary liver cancer is a common kind of digestive cancers with high malignancy, causing 745,500 deaths each year.
Hepatocellular carcinoma is the major pathological type of primary liver cancer.
Traditional treatment methods for patients with hepatocellular carcinoma have shown poor efficacy in killing residual cancer cells for a long time.
In recent years, tumor immunotherapy has emerged as a promising method owing to its safety and efficacy with respect to delaying the progression of advanced tumors and protecting postoperative patients against tumor relapse and metastasis.
Immune tolerance and suppression in tumor microenvironments are the theoretical basis of immunotherapy.
Adoptive cell therapy functions by stimulating and cultivating autologous lymphocytes ex vivo and then reinfusing them into the patient to kill cancer cells.
Cancer vaccination is performed using antigenic substances to activate tumor-specific immune responses.
Immune checkpoint inhibitors can reactivate tumor-specific T cells and develop an antitumor effect by suppressing checkpoint-mediated signaling.
Oncolytic viruses may selectively replicate in tumor cells and cause lysis without harming normal tissues.
Here, we briefly introduce the mechanism of immunosuppression in hepatocellular carcinoma and summarize the rationale of the four major immunotherapeutic approaches with their current advances.
American Psychological Association (APA)
Xie, Yingjun& Xiang, Yien& Sheng, Jiyao& Zhang, Dan& Yao, Xiaoxiao& Yang, Yongsheng…[et al.]. 2018. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1193146
Modern Language Association (MLA)
Xie, Yingjun…[et al.]. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. Journal of Immunology Research No. 2018 (2018), pp.1-8.
https://search.emarefa.net/detail/BIM-1193146
American Medical Association (AMA)
Xie, Yingjun& Xiang, Yien& Sheng, Jiyao& Zhang, Dan& Yao, Xiaoxiao& Yang, Yongsheng…[et al.]. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1193146
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1193146